Press releases

Boston Scientific Corporation (NYSE: BSX) will participate in TD Cowen's 46th Annual Health Care Conference on Tuesday, March 3, 2026. Mike Mahoney, chairman and chief executive officer, and...

“2025 was another exceptional year for Boston Scientific,” said Mike Mahoney, chairman and CEO.

Three clinical studies reinforce the sustained impact and efficacy of spinal cord stimulation (SCS) for treating chronic pain

Acquisition to expand Boston Scientific's cardiovascular portfolio and further address increasing prevalence of vascular diseases Provides scaled entry into mechanical thrombectomy and...

Acquisition to expand urology offerings for people living with overactive bladder MARLBOROUGH, Mass., Jan. 12, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has...

A live webcast and replay will be available for the January 13 conference session and the February 4 conference call

Webcasts of the November 18 and December 25 investor conference sessions will be available. Learn how to tune in live or watch the replays.

"We delivered a quarter marked by exceptional performance,” said Mike Mahoney, chairman and CEO.

Acquisition to expand the neuromodulation offerings for people living with chronic pain

Boston Scientific Corporation (NYSE: BSX) will host a meeting with the investor community to review its financial goals and long-term growth strategies on Tuesday, September 30, 2025.

MARLBOROUGH, Mass., Aug. 6, 2025 – Boston Scientific Corporation (NYSE: BSX) today announced data from a recent national survey of 2,000 U.S. women between the ages of 30 and 65, which examined...

"This was another excellent quarter, marked by exceptional top-line performance,” said chairman and CEO Mike Mahoney

The FARAPULSE PFA System now approved for pulmonary vein and posterior wall ablation in patients with persistent atrial fibrillation

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2025, on Wednesday, July 23,...

Boston Scientific will participate in two upcoming investor conferences in May 2025. A live webcast and replay will be available for each event. Read more.

Trial achieves positive results in the treatment of persistent atrial fibrillation.

After 30 successful years with Boston Scientific, Dan will work closely with CFO successor Jon Monson to ensure a smooth transition.

"We delivered an exceptional quarter to start the year,” said Mike Mahoney, chairman and CEO, Boston Scientific.

Boston Scientific will webcast its conference call with financial results and business highlights for Q1 ended March 31, 2025. Learn how to tune in.

Acquisition to expand Interventional Cardiology Therapies offerings with ultrasound-based renal denervation therapy for treatment of hypertension

Boston Scientific Corporation (the "Company") (NYSE: BSX) today announced that American Medical Systems Europe B.V. ("AMS Europe"), its wholly owned finance subsidiary, has completed a public...

Boston Scientific Corporation (NYSE: BSX) announced the pricing of a public offering of senior notes.

Boston Scientific will participate in the upcoming healthcare conference in Marach 2025.

"2024 was one of the best years in the history of Boston Scientific,” said Mike Mahoney, chairman and CEO.

Data sets for two clinical trials show positive results for both FARAPULSE pulsed field ablation and the WATCHMAN device for treating Afib.